Makers Laboratories Sets November 4 Q2 Results Review

Makers Laboratories Limited will consider unaudited Q2 and first-half FY27 results on November 4, 2026, after reporting consolidated net profit of ₹1.50 crore in the June 2026 quarter, up 240.91% year-on-year. The meeting will show whether the company maintained its improved revenue, earnings and operating performance through the September quarter.

When will Makers Laboratories announce Q2 FY27 results?

Makers Laboratories will hold a board meeting on Wednesday, November 4, 2026, to consider and approve its standalone and consolidated unaudited financial results for the quarter and half year ended September 30, 2026. The company disclosed the meeting schedule to BSE on October 21, 2026.

The announcement is significant because it is the first scheduled update after the June 2026 quarter, when Makers Laboratories reported higher consolidated sales and profit. Investors will receive the September-quarter figures along with half-year financial data once the board has considered the results.

The company has also closed its trading window for designated persons from October 1, 2026. The window will remain shut until 48 hours after the declaration of the financial results, which the company indicated would be until November 6, 2026. Such restrictions are part of insider-trading compliance around price-sensitive financial information.

What did Makers Laboratories report in the June 2026 quarter?

Makers Laboratories reported consolidated net sales of ₹42.77 crore for the quarter ended June 2026, a 22.20% increase from ₹35.00 crore in the corresponding quarter a year earlier. Consolidated net profit rose 240.91% year-on-year to ₹1.50 crore from ₹0.44 crore.

EBITDA stood at ₹7.57 crore in the June 2026 quarter, compared with ₹3.28 crore in the June 2025 quarter, an increase of 130.79%. Earnings per share improved to ₹2.55 from ₹0.74 over the same comparison. These reported figures provide the immediate base for assessing the September-quarter result.

Separate financial data cited for the latest quarter showed revenue of ₹42.77 crore and net income of ₹1.50 crore. It also indicated that quarterly revenue increased from ₹36.03 crore in the preceding quarter to ₹42.77 crore in June 2026, while net income rose from ₹1.09 crore to ₹1.50 crore. The November 4 filing will clarify the next stage of this quarterly trend.

Why are the September-quarter results important for investors?

The September-quarter results matter because they will indicate whether the June-quarter increase in sales, EBITDA and net profit was sustained. The available June data showed that earnings grew faster than revenue on a year-on-year basis, making operating profitability an important item to monitor in the upcoming filing.

Investors will also be able to compare the standalone and consolidated results approved by the board. The company has specifically stated that both sets of unaudited results for Q2 and the first half of FY27 will be considered. Until the filing is released, figures for the September quarter, including revenue, net profit and EPS, have not been disclosed.

The board-meeting notice does not announce a dividend, capital-raising exercise or any change in business strategy. Therefore, the scheduled event is limited to consideration and approval of the financial statements for the stated period. Any capital-allocation details would need to come from the results filing or accompanying disclosures.

What is the background to Makers Laboratories' recent financial trend?

Makers Laboratories' reported June-quarter figures followed a period of uneven earnings in the data provided. The company recorded annual revenue of ₹1,408.73 million, or about ₹140.87 crore, in the fiscal year ended March 2026 according to the cited income-statement data. That annual figure gives context to the June-quarter revenue of ₹42.77 crore.

The June 2026 quarterly release showed a marked improvement from the year-earlier period, particularly in net profit and EBITDA. However, a single quarter does not establish a full-year trend. The half-year results due on November 4 will provide a broader view of reported sales and profitability over the first six months of FY27.

On October 12, 2026, Makers Laboratories also informed BSE that it had received a certificate from MUFG Intime India Private Limited, formerly Link Intime India Private Limited. The certificate confirmed compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026.

How does the board meeting affect market participants?

For shareholders, the results date creates a defined point at which updated financial information will become available. The key reported June benchmarks are ₹42.77 crore in consolidated net sales, ₹7.57 crore in EBITDA, ₹1.50 crore in net profit and ₹2.55 in EPS. The September-quarter outcome can be assessed against those figures once disclosed.

For the company, the process involves board approval of unaudited standalone and consolidated statements, followed by market disclosure. The insider trading-window closure is intended to limit dealing by designated persons while unpublished price-sensitive information is being prepared and reviewed.

The information available does not establish how the market will react to the results. It does, however, set out the factors that investors can evaluate after the filing: revenue movement, operating-profit conversion, net profit, EPS and any management disclosures on capital allocation or business operations.

Conclusion

Makers Laboratories will place its Q2 and H1 FY27 unaudited standalone and consolidated results before the board on November 4, following a June quarter in which consolidated net sales rose 22.20% year-on-year and net profit increased 240.91% to ₹1.50 crore. The scheduled disclosure will provide the next confirmed measure of the company's financial performance.

The main item to watch is whether the operating and profit improvement reported in June continued through the quarter ended September 30, 2026. Investors can also watch for any disclosures on capital allocation when the results are approved, while the trading window is scheduled to reopen after November 6, 2026.